(3R,4S,5S)-3-amino-4-hydroxy-5-(4-hydroxy-3-(hydroxymethyl)benzyl)tetrahydro-2H-thiopyran 1,1-dioxide | 1292799-26-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3R,4S,5S)-3-amino-4-hydroxy-5-(4-hydroxy-3-(hydroxymethyl)benzyl)tetrahydro-2H-thiopyran 1,1-dioxide
• CAS: 1292799-26-8
• 化学式: C₁₃H₁₉NO₅S
• 分子量: 301.364
• InChiKey: PRFMPXGBLNGIPI-MDZLAQPJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.84
• 重原子数：
  20.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  120.85
• 氢给体数：
  4.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  (3R,4S,5S)-3-amino-4-hydroxy-5-(4-hydroxy-3-(hydroxymethyl)benzyl)tetrahydro-2H-thiopyran 1,1-dioxide 、 3-异丙基苯甲醛 在 sodium acetate 、 sodium cyanoborohydride 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 (3S,4S,5R)-3-(4-hydroxy-3-hydroxymethyl-benzyl)-5-(3-isopropyl-benzylamino)-1,1-dioxo-hexahydro-1λ6-thiopyran-4-ol
  参考文献：
  名称：

  Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors

  摘要：

  This Letter describes the de novo design of non-peptidic hydroxyethylamine (HEA) inhibitors of BACE-1 by elimination of P-gp contributing amide attachments. The predicted binding mode of the novel cyclic sulfone HEA core template was confirmed in a X-ray co-crystal structure. Inhibitors of sub-micromolar potency with an improved property profile over historic HEA inhibitors resulting in improved brain penetration are described. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.038
• 作为产物：
  描述：

  在 盐酸 、 水 、 三溴化硼 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 (3R,4S,5S)-3-amino-4-hydroxy-5-(4-hydroxy-3-(hydroxymethyl)benzyl)tetrahydro-2H-thiopyran 1,1-dioxide
  参考文献：
  名称：

  Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors

  摘要：

  This Letter describes the de novo design of non-peptidic hydroxyethylamine (HEA) inhibitors of BACE-1 by elimination of P-gp contributing amide attachments. The predicted binding mode of the novel cyclic sulfone HEA core template was confirmed in a X-ray co-crystal structure. Inhibitors of sub-micromolar potency with an improved property profile over historic HEA inhibitors resulting in improved brain penetration are described. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.038